The Industrialization of Telehealth: A Strategic Analysis of the Ro and Hims & Hers Duopoly
The traditional American pharmaceutical supply chain operates as a fortress of opacity, defended by a complex triad of pharmacy benefit […]
The Inflation Reduction Act Pill Penalty: Structural Distortions in Pharmaceutical R&D and Strategic Pricing Adaptations
The enactment of the Inflation Reduction Act (IRA) of 2022 represents a paradigmatic shift in the United States biopharmaceutical landscape,
Stop the Patent Cliff
The global pharmaceutical industry reached a valuation of $1.6 trillion in 2023.1 Projections show this market will hit $2.35 trillion
Stop the Patent Cliff Read Post »
The Defensive Architecture of Biopharmaceutical Monopolies: A Strategic Analysis of the ‘Patent Wall’
The global pharmaceutical landscape is currently navigating a period of unprecedented fiscal exposure, characterized by a looming “super-cliff” of patent
Stop patent thickets to lower drug costs
The pharmaceutical industry has moved away from the traditional model of innovation where a single patent protects a drug for
Stop patent thickets to lower drug costs Read Post »
Policy Solutions to End Patent Thickets: Examining Legislative Proposals to Boost Generic Competition
The pharmaceutical industry in 2026 stands at a critical juncture where the traditional “patent cliff”—the once-dreaded moment when a blockbuster
505(b)(2) Surprises: An Overlooked Pain Point for Drug Investors
The Strategic Bridge: Unpacking the 505(b)(2) Paradox A “Hybrid” Revolution: Defining the 505(b)(2) In the complex and resource-intensive world of
505(b)(2) Surprises: An Overlooked Pain Point for Drug Investors Read Post »
Biosimilar Market Timing: The Investor’s Clock-Watching Pain Point
The Investor’s Clock-Watching Pain Point: Understanding the Core Challenge Setting the Stage: The Promise vs. The Reality For too long,
Biosimilar Market Timing: The Investor’s Clock-Watching Pain Point Read Post »
Valuation Volatility: The Pharma Investor’s Persistent Pain Point
A Ticking Time Bomb in the Balance Sheet The world of pharmaceutical finance is unlike any other. When we talk
Valuation Volatility: The Pharma Investor’s Persistent Pain Point Read Post »
